Thus, in many cell-based and in vivo studies, FABP5 deletion, knockdown, or inhibition has been shown to reduce cell proliferation, including in PC (132), glioma (180), colorectal cancer (153), gastric cancer (201), lung adenocarcinoma (52), and renal clear cell carcinoma (114). Here, FABP5 is linked to central nervous system cancer.